SpringerLink
Log in

Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment

  • RESEARCH NOTE
  • Published:
Journal of Genetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  • Ambrosio B., Hernandez C., Novelletto A., Dugoujon J. M., Rodriguez J. N., Cuesta P. et al. 2010 Searching the peopling of the Iberian Peninsula from the perspective of two andalusian subpopulations: a study based on Y-chromosome haplogroups J and E. Coll. Antropol. 34, 1215–1228.

    PubMed  Google Scholar 

  • Andriole G. L. and Kirby R. 2003 Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. 44, 82–88.

    Article  CAS  PubMed  Google Scholar 

  • Andriole G. L., Bostwick D. G., Brawley O. W., Gomella L. G., Marberger M., Montorsi F. et al. 2010 Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192–1202.

    Article  CAS  PubMed  Google Scholar 

  • Barrett J. C., Fry B., Maller J. and Daly M. J. 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265.

    Article  CAS  PubMed  Google Scholar 

  • Clayton D. 2012 snpStats: SnpMatrix and XSnpMatrix classes and methods. R package version 1.8.1. Available at: http://www.bioconductor.org/packages/release/bioc/html/snpStats.html .

  • Cussenot O., Azzouzi A. R., Nicolaiew N., Mangin P., Cormier L., Fournier G. et al. 2007 Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur. Urol. 52, 1082–1087.

    Article  PubMed  Google Scholar 

  • Edwards J. E. and Moore R. A. 2002 Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2, 14.

    Article  PubMed Central  PubMed  Google Scholar 

  • Giwercman Y. L., Abrahamsson P. A., Giwercman A., Gadaleanu V. and Ahlgren G. 2005 The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur. Urol. 48, 679–685.

    Article  CAS  PubMed  Google Scholar 

  • Henriquez-Hernandez L. A., Valenciano A., Foro-Arnalot P., Alvarez-Cubero M. J., Cozar J. M., Suarez-Novo J. F. et al. 2013a Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies. PLoS One 8, e69735.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Henriquez-Hernandez L. A., Valenciano A., Herrera-Ramos E., Lloret M., Riveros-Perez A. and Lara P. C. 2013b High-throughput genoty** system as a robust and useful tool in oncology: experience from a single institution. Biologicals 41, 424–429.

    Article  CAS  PubMed  Google Scholar 

  • Huggins C. 1967 Endocrine-induced regression of cancers. Cancer Res. 27, 1925–1930.

    CAS  PubMed  Google Scholar 

  • Lindstrom S., Wiklund F., Adami H. O., Balter K. A., Adolfsson J. and Gronberg H. 2006 Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res. 66, 11077– 11083.

    Article  PubMed  Google Scholar 

  • Ma Q. and Lu A. Y. 2011 Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 63, 437– 459.

    Article  CAS  PubMed  Google Scholar 

  • McConnell J. D. 1995 Prostatic growth: new insights into hormonal regulation. Br. J. Urol. 76 suppl 1, 5–10.

    CAS  PubMed  Google Scholar 

  • Morcillo-Suarez C., Alegre J., Sangros R., Gazave E, de Cid R., Milne R. et al. 2008 SNP analysis to results (SNPator): a web-based environment oriented to statistical genomic analyses upon SNP data. Bioinformatics 24, 1643–1644.

    Article  CAS  PubMed  Google Scholar 

  • Neslund-Dudas C., Bock C. H., Monaghan K., Nock N. L., Yang J. J., Rundle A. et al. 2007 SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67, 1654–1663.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Onen I. H., Ekmekci A., Eroglu M., Polat F. and Biri H. 2007 The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 26, 100–107.

    Article  CAS  PubMed  Google Scholar 

  • Rando J. C., Cabrera V. M., Larruga J. M., Hernandez M., Gonzalez A. M., Pinto F. et al. 1999 Phylogeographic patterns of mtDNA reflecting the colonization of the Canary Islands. Ann. Hum. Genet. 63, 413–428.

    Article  CAS  PubMed  Google Scholar 

  • Stanbrough M., Bubley G. J., Ross K., Golub T. R., Rubin M. A., Penning T. M. et al. 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815–2825.

    Article  CAS  PubMed  Google Scholar 

  • Thomas L. N., Lazier C. B., Gupta R., Norman R. W., Troyer D. A., O’Brien S. P. et al. 2005 Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63, 231–239.

    Article  CAS  PubMed  Google Scholar 

  • Thompson I. M., Goodman P. J., Tangen C. M., Lucia M. S., Miller G. J., Ford L. G. et al. 2003 The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224.

    Article  CAS  PubMed  Google Scholar 

  • Titus M. A., Gregory C. W., Ford 3. O. H., Schell M. J., Maygarden S. J. and Mohler J. L. 2005 Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11, 4365–4371.

    Article  CAS  PubMed  Google Scholar 

  • Walsh P. C. 2010 Chemoprevention of prostate cancer. N. Engl. J. Med. 362, 1237–1238.

    Article  CAS  PubMed  Google Scholar 

  • Yasuda S. U., Zhang L. and Huang S. M. 2008 The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharmacol. Ther. 84, 417–423.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was subsidized by the grant from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad from Spain), ID: PI12/01867. Almudena Valenciano has a grant from the Instituto Canario de Investigación del Cáncer (ICIC). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the technical support from the Immunology Department (Hospital Universitario de Gran Canaria, Dr Negrín) staff: Nereida González-Quevedo and Yanira Florido-Ortega.

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, 35010, Spain

    LUIS ALBERTO HENRÍQUEZ-HERNÁNDEZ & PEDRO C. LARA

  2. Instituto Canario de Investigación del Cáncer, Las Palmas, 38204, Spain

    LUIS ALBERTO HENRÍQUEZ-HERNÁNDEZ, ALMUDENA VALENCIANO & PEDRO C. LARA

  3. Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

    LUIS ALBERTO HENRÍQUEZ-HERNÁNDEZ & PEDRO C. LARA

  4. Institud d’Oncologia Radioteràpica, Hospital de la Esperanza, Parc de Salut Mar, Barcelona, 08003, Spain

    PALMIRA FORO-ARNALOT

  5. Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Facultad de Medicina, Universidad de Granada, Granada, 18012, Spain

    MARÍA JESÚS ÁLVAREZ-CUBERO

  6. GENYO, Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research, Granada, 18016, Spain

    MARÍA JESÚS ÁLVAREZ-CUBERO

  7. Department of Urology, Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain

    JOSÉ MANUEL COZAR

  8. Department of Urology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, 08907, Spain

    JOSÉ FRANCISCO SUÁREZ-NOVO & MANEL CASTELLS-ESTEVE

  9. Radiation Oncology Department, Onkologikoa, Guipuzcoa, 20014, Spain

    PABLO FERNÁNDEZ-GONZALO & BELÉN DE-PAULA-CARRANZA

  10. Health Services Research Group, Institut de Recerca Hospital del Mar (IMIM), Barcelona, 08003, Spain

    MONTSE FERRER

  11. Department of Radiation Oncology, Institut Català d’Oncologia (ICO), L’Hospitalet de Llobregat, 08907, Spain

    FERRÁN GUEDEA

  12. Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, 08026, Spain

    GEMMA SANCHO-PARDO & JORDI CRAVEN-BARTLE

  13. Radiation Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain

    MARÍA JOSÉ ORTIZ-GORDILLO & PATRICIA CABRERA-ROLDÁN

  14. Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, 35010, Spain

    ESTEFANÍA HERRERA-RAMOS & CARLOS RODRÍGUEZ-GALLEGO

  15. Department of Medical and Surgical Sciences, Universidad de Las Palmas de Gran Canaria, Las Palmas, 35016, Spain

    ESTEFANÍA HERRERA-RAMOS & CARLOS RODRÍGUEZ-GALLEGO

Authors
  1. LUIS ALBERTO HENRÍQUEZ-HERNÁNDEZ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ALMUDENA VALENCIANO
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PALMIRA FORO-ARNALOT
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. MARÍA JESÚS ÁLVAREZ-CUBERO
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. JOSÉ MANUEL COZAR
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JOSÉ FRANCISCO SUÁREZ-NOVO
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. MANEL CASTELLS-ESTEVE
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. PABLO FERNÁNDEZ-GONZALO
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. BELÉN DE-PAULA-CARRANZA
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. MONTSE FERRER
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. FERRÁN GUEDEA
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. GEMMA SANCHO-PARDO
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. JORDI CRAVEN-BARTLE
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. MARÍA JOSÉ ORTIZ-GORDILLO
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. PATRICIA CABRERA-ROLDÁN
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. ESTEFANÍA HERRERA-RAMOS
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. CARLOS RODRÍGUEZ-GALLEGO
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. PEDRO C. LARA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to LUIS ALBERTO HENRÍQUEZ-HERNÁNDEZ.

Additional information

Henrquez-Hernández L. A., Valenciano A., Foro-Arnalot P., Álvarez-Cubero M. J., Cozar J. M., Suárez-Novo J. F., Castells-Esteve M., Fernández-Gonzalo P., De-Paula-Carranza B., Ferrer M., Guedea F., Sancho-Pardo G., Craven-Bartle J., Ortiz-Gordillo M. J., Cabrera-Roldán P., Herrera-Ramos E., Rodríguez-Gallego C. and Lara P. C. 2015 Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment. J. Genet. 94, xx–xx

Electronic supplementary material

Below is the link to the electronic supplementary material.

(PDF 823 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

HENRÍQUEZ-HERNÁNDEZ, L.A., VALENCIANO, A., FORO-ARNALOT, P. et al. Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment. J Genet 94, 335–341 (2015). https://doi.org/10.1007/s12041-015-0511-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12041-015-0511-3

Keywords

Search

Navigation